<?xml version="1.0" encoding="UTF-8"?>
<p>Blockade of renin‐angiotensin‐aldosterone system is a pivotal strategy to manage congestive heart failure (CHF). Angiotensin‐receptor blockers (ARBs) are perceived to offer more complete neurohormonal suppression in the treatment of CHF by directly occupying angiotensin II receptor sites. However, whether the combination therapy of ARBs with current CHF treatments has clinically incremental benefits, is unknown in dogs with myxomatous mitral valve disease (MMVD).</p>
